COST-EFFECTIVENESS OF NILOTINIB VERSUS IMATINIB AS FIRST-LINE TREATMENT FOR NEWLY DIAGNOSED PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH plus ) CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE (CML-CP) IN RUSSIAN FEDERATION

被引：0
|
作者：
Yagudina, R. [1 ]
Kulikov, A. [1 ]
Komarov, I [1 ]
机构：
[1] IM Sechenov First Moscow State Med Univ, Moscow, Russia
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 07期
关键词：
D O I：
10.1016/j.jval.2012.08.2132
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A426 / A426
页数：1
相关论文
共 50 条
  • [41] Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up
    R A Larson
    A Hochhaus
    T P Hughes
    R E Clark
    G Etienne
    D-W Kim
    I W Flinn
    M Kurokawa
    B Moiraghi
    R Yu
    R E Blakesley
    N J Gallagher
    G Saglio
    H M Kantarjian
    Leukemia, 2012, 26 : 2197 - 2203
  • [42] Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in ehronic phase (CML-CP): ENESTnd beyond one year
    Larson, R. A.
    le Coutre, P. D.
    Reiffers, J.
    Hughes, T. P.
    Saglio, G.
    Edrich, P.
    Hoenekopp, A.
    Gallagher, N. J.
    Kantarjian, H.
    Hochhaus, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [43] Cardiac Safety Profile of Imatinib and Nilotinib In Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Results From ENESTnd.
    Larson, Richard A.
    Hochhaus, Andreas
    Saglio, Giuseppe
    Rosti, Gianantonio
    Lopez, Jose L.
    Stenke, Leif
    Nakamae, Hirohisa
    Goldberg, Stuart L.
    Wang, Ming-Chung
    Gallagher, Neil J.
    Hoenekopp, Albert
    Ortmann, Christine-Elke
    Hughes, Timothy P.
    Kantarjian, Hagop M.
    BLOOD, 2010, 116 (21) : 944 - 945
  • [44] High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia
    Kantarjian, H
    Talpaz, M
    O'Brien, SS
    Garcia-Manero, G
    Verstovsek, S
    Giles, F
    Rios, MB
    Shan, JQ
    Letvak, L
    Thomas, D
    Faderl, S
    Ferrajoli, A
    Cortes, J
    BLOOD, 2004, 103 (08) : 2873 - 2878
  • [45] Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia
    Gugliotta, Gabriele
    Castagnetti, Fausto
    Breccia, Massimo
    Gozzini, Antonella
    Usala, Emilio
    Carella, Angelo M.
    Rege-Cambrin, Giovanna
    Martino, Bruno
    Abruzzese, Elisabetta
    Albano, Francesco
    Stagno, Fabio
    Luciano, Luigia
    D'Adda, Mariella
    Bocchia, Monica
    Cavazzini, Francesco
    Tiribelli, Mario
    Lunghi, Monia
    Falcone, Antonietta Pia
    Musolino, Caterina
    Levato, Luciano
    Venturi, Claudia
    Soverini, Simona
    Cavo, Michele
    Alimena, Giuliana
    Pane, Fabrizio
    Martinelli, Giovanni
    Saglio, Giuseppe
    Rosti, Gianantonio
    Baccarani, Michele
    AMERICAN JOURNAL OF HEMATOLOGY, 2016, 91 (06) : 617 - 622
  • [46] COMPARATIVE EFFICACY OF IMATINIB, DASATINIB AND NILOTINIB FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): A META-ANALYSIS AND INDIRECT COMPARISON
    Park, J.
    Kwon, H.
    Shin, M.
    Shin, S.
    Lee, J. Y.
    VALUE IN HEALTH, 2015, 18 (07) : A433 - A433
  • [47] Deep Molecular Response in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated With Nilotinib: ENESTnext Update
    Mauro, Michael J.
    Dakhil, Shaker
    Cortes, Jorge E.
    Rizzieri, David A.
    Keir, Christopher H.
    Yi, Sandy
    Heinrich, Michael C.
    Goldberg, Stuart L.
    Catchatourian, Rosalind
    Kuriakose, Philip
    Radich, Jerald P.
    BLOOD, 2014, 124 (21)
  • [48] Justification for Asciminib Dosing in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (Ph plus CML-CP) with and without the T315I Mutation
    Combes, Francois Pierre
    Li, Ying Fei
    Sy, Sherwin K. B.
    Lorenzo, Sebastien
    Dasgupta, Kohinoor
    Kapoor, Shruti
    Hoch, Matthias
    Ho, Yu-Yun
    BLOOD, 2022, 140 : 6791 - 6792
  • [49] Change in Chronic Low-Grade Nonhematologic Adverse Events (AEs) and Quality of Life (QoL) in Adult Patients (pts) with Philadelphia Chromosome-Positive (Ph plus ) Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Switched From Imatinib (IM) to Nilotinib (NIL)
    Cortes, Jorge E.
    Lipton, Jeffrey H.
    Miller, Carole B.
    Ailawadhi, Sikander
    Akard, Luke
    Pinilla-Ibarz, Javier
    Lin, Felice P.
    Ericson, Solveig G.
    Mauro, Michael J.
    BLOOD, 2012, 120 (21)
  • [50] Efficacy and Safety of Nilotinib in elderly patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) with Imatinib Resistance or Intolerance
    Ottmann, O. G.
    le Coutre, P.
    Gattermann, N.
    Hochhaus, A.
    Bruemmendorf, T. H.
    Kindler, T.
    Duyster, J.
    Al-Ali, H.
    Lipton, J.
    Wang, J.
    Yang, M.
    Szczudlo, T.
    Giles, F.
    ONKOLOGIE, 2010, 33 : 138 - 138
12345